By Lauran Neergaard

Hospital workers begin unloading precious frozen vials of COVID-19 vaccine Monday, with the first vaccinations against a scourge that has killed nearly 300,000 Americans expected later in the day.

“It feels like the cavalry is arriving,” Robert C. Garrett, CEO of Hackensack Meridian Health, said as New Jersey’s largest health network awaited delivery.

Shots made by Pfizer Inc. and its German partner BioNTech are the first authorized for emergency use by the Food and Drug Administration -- beginning what will become the largest vaccination campaign in U.S. history. Several other countries also have OK'd the vaccine, including the U.K., which started vaccinating last week.

For health care workers who, along with nursing home residents, will be first in line for vaccination, hope is tempered by grief and the sheer exhaustion of months spent battling a coronavirus that still is surging in the U.S. and around the world.

“This is mile 24 of a marathon. People are fatigued. But we also recognize that this end is in sight,” said Dr. Chris Dale of Swedish Health Services in Seattle.

Packed in dry ice to stay at ultra-frozen temperaturesthe first of nearly 3 million doses being shipped in staggered batches this week made their way by truck and by plane around the country Sunday from Pfizer’s Kalamazoo, Michigan, factory. Once they arrive at distribution centers, each state directs where the doses go next.

Some hospitals across the country spent the weekend tracking their packages, refreshing FedEx and UPS websites for clues.

More of the Pfizer-BioNTech vaccine will arrive each week. And later this week, the FDA will decide whether to green light the world’s second rigorously studied COVID-19 vaccine, made by Moderna Inc.

Now the hurdle is to rapidly get vaccine into the arms of millions, not just doctors and nurses but other at-risk health workers such as janitors and food handlers — and then deliver a second dose three weeks later.

“We’re also in the middle of a surge, and it’s the holidays, and our health care workers have been working at an extraordinary pace,” said Sue Mashni, chief pharmacy officer at Mount Sinai Health System in New York City.

Plus, the shots can cause temporary fever, fatigue and aches as they rev up people's immune systems, forcing hospitals to stagger employee vaccinations.

A wary public will be watching closely to see whether health workers embrace vaccination. Just half of Americans say they want to get vaccinated, while about a quarter don’t and the rest are unsure, according to a recent poll by The Associated Press-NORC Center for Public Health Research.

The FDA, considered the world’s most strict medical regulator, said the Pfizer-BioNTech vaccine appears safe and strongly protective -- and laid out the data behind it in a daylong public meeting last week for scientists and consumers alike to see.

“Please people, when you look back in a year and you say to yourself, ‘Did I do the right thing?’ I hope you’ll be able to say, ‘Yes, because I looked at the evidence,’” Dr. Francis Collins, director of the National Institutes of Health, said Sunday on NBC’s Meet the Press. “People are dying right now. How could you possibly say, ‘Let’s wait and see.’”

Still, emergency use means the vaccine was cleared for widespread use before a final study in nearly 44,000 people is complete -- and that research is continuing to try to answer additional questions. While effective against COVID-19 illness, it’s not yet clear if vaccination will stop the symptomless spread that accounts for half of all cases.

The shots still must be studied in children, and during pregnancy. But the American College of Obstetricians and Gynecologists said late Sunday that vaccination should not be withheld from pregnant women who otherwise would qualify.

While the vaccine was determined to be safe, regulators in the U.K. are investigating several severe allergic reactions. The FDA’s instructions tell providers not to give it to those with a known history of severe allergic reactions to any of its ingredients.

AP journalists Tamara Lush and Kathy Young contributed to this report.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
What We Know About the Omicron Variant of COVID-19
Dr. Farhan Bhatti, a family physician and Michigan State lead for the Committee to Protect Health Care, joined Cheddar to discuss the newly discovered and highly transmissible omicron variant of COVID-19. Bhatti said it is too early to draw any conclusions about the new variant but there is concern that it could eventually mutate and develop a resistance to vaccines. "Time will tell, but for now, it looks like, still, the best thing that we can do to try to limit the spread of this disease is make sure everybody gets a vaccine and make sure everybody avoids large gatherings indoors and wears masks during the wintertime especially," he said.
Omicron Risk, Barbados Drops Queen & Jack Logs Off
Jill and Carlo cover the latest developments with the Omicron variant that are spooking markets once again. Twitter's @Jack is leaving, SCOTUS takes up abortion rights and the world has a brand new republic.
CDC: All U.S. Adults Eligible for Pfizer and Moderna Boosters
A CDC panel unanimously endorsed Moderna and Pfizer Covid-19 vaccine boosters for all U.S. adults. This comes after the FDA gave its own authorization for everyone 18 and older, scrapping previous eligibility factors like age and underlying conditions. Dr. Shereef Elnahal, President and CEO of University Hospital and former New Jersey Health Commissioner, joined Cheddar News to break down the development.
U.S. to Buy 10 Million Courses of Pfizer Covid Pill
The Biden Administration is set to buy 10 million courses of Pfizer's Covid pill if it gains emergency use authorization from the FDA. With this purchase, the U.S. will receive more than 13 million courses of antiviral pills aimed at treating Covid and reducing severe illness and death. Pfizer's pill has been shown to reduce risk of hospitalization and death by 89 percent, proving it could be a key tool in the fight against the pandemic. Dr. Soumi Eachempati, Co-Founder, CEO & CMO of Cleared4, joined Cheddar News to discuss.
New Covid Variant Sends Markets Falling as Investor Concerns Deepen
Friday saw big sell offs, with the Dow Jones posting its worst day since October 2020, falling 905 points, with the Nasdaq and S&P 500 each tumbling more than two percent as well. Much of that due to investor concerns over the new Covid-19 'Omicron' variant first detected in South Africa. Craig Erlam, senior market analyst at Oanda explains what investors should expect this week.
National Geographic's Dr. Sylvia Earle Talks the State of Our Oceans
The ocean is an important topic when it comes to the climate. It plays a vital role in shaping our environment, with rising sea levels causing a 35% increase in natural disasters around the world, affecting 1.7 billion people. Dr. Sylvia Earle has been called perhaps the greatest advocate our oceans have ever had, with Time magazine dubbing her its first 'hero of the planet' and the Library of Congress naming her a living legend. She is also the founder of Mission Blue, an organization that inspires action to explore and protect the ocean. Dr. Earle joined Cheddar Climate for more on the importance of caring for the ocean and its impact on climate change.
Omicron Variant Alarms Scientists Around The World
Scientists are racing to understand the Omicron variant of covid-19 and find out just how dangerous it really is. Omicron, dubbed a variant of concern by the WHO, was first detected in South Africa last week and has already spread to multiple countries, including the UK, Canada, Australia and more. Dr. Jonathan Javitt, CEO of Nrx and adjunct professor at Johns Hopkins School of Medicine, joined Cheddar to discuss what we know and don't know about this new variant.
Biggest Climate Change Investment In U.S. History
The House has officially passed the $1.75 trillion social policy and climate big. This new bill is expected to bring some huge investments into working towards fighting climate change. U.S. President of We Don't Have Time, Sweta Chakraborty, joined Cheddar to discuss more.
Load More